<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00233480</url>
  </required_header>
  <id_info>
    <org_study_id>UCLA IRB #04-12-007-01</org_study_id>
    <secondary_id>1K23HL085097-01A1</secondary_id>
    <nct_id>NCT00233480</nct_id>
  </id_info>
  <brief_title>Statin Therapy in Heart Failure: Potential Mechanisms of Benefit</brief_title>
  <official_title>A Double-blind Randomized, Placebo-Controlled, Single-Center Study to Assess the Impact of Statins on the Autonomic Nervous System and Cardiac Structure/Function in Non-Ischemic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the investigators' study is to further understand the potentially beneficial
      effects of statin therapy in patients with heart failure. It is hypothesized that statins
      will 1) increase the heart's pumping ability 2) improve functioning of the sympathetic
      nervous system and 3) decrease immune activation in heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent evidence suggests that HMG-Coenzyme A (statin) therapy may be associated with improved
      survival in both ischemic and non-ischemic heart failure (HF). Large, randomized outcome
      studies of statins in HF are currently underway, but these trials will not address underlying
      mechanisms. The aim of the study is to investigate statins' potentially beneficial mechanisms
      of action in HF, focusing on: 1) sympathetic nervous system activation and 2) myocardial
      remodeling, and 3) immune activation in heart failure.

      Fifty patients with systolic HF of non-ischemic etiology from a single center will be
      randomized in a double-blinded fashion to 3 months of atorvastatin 10mg QD (25 subjects) vs
      matching placebo QD (25 subjects). The following exams will be performed at baseline
      (pre-treatment) and at end of study (post-treatment): sympathetic microneurography,
      echocardiography, and peripheral blood chemokine analysis. Sympathetic microneurography at
      the peroneal nerve will directly quantify changes in sympathetic nerve activity
      (bursts/minute). Echocardiography (with the addition of MRI in a subset of subjects without
      pacemakers or implantable defibrillators) will be used to track changes in cardiac structure
      and function; indices of remodeling will include measurement of left ventricular mass index,
      left ventricular volume indices, left ventricular ejection fraction, and subendocardial scar
      quantification (MRI only). Immune activation will be characterized by circulating cytokines
      and chemokines. Additionally, quantification of established cardiac biomarkers (cardiac
      troponin, B-type natriuretic peptide, and C-reactive Protein), Holter monitor/heart rate
      variability studies, and quality of life and global clinical assessment will be performed
      pre- and post- treatment.

      Neither sympathetic microneurography nor MRI have been previously utilized to assess statins'
      effects in humans with HF. The impact of statin therapy on inflammatory chemokine activation
      in HF also has not been studied. The knowledge gained from our proposed investigations may
      serve as a basis for understanding how statin therapy has potential to improve clinical
      outcomes in HF, and may ultimately lead to new therapeutic strategies for HF.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LVEF (Left Ventricular Ejection Fraction)</measure>
    <time_frame>baseline and three months</time_frame>
    <description>Left ventricular ejection fraction was assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle Sympathetic Nerve Activity (by Sympathetic Microneurography)</measure>
    <time_frame>Baseline and three months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular End-diastolic Dimension (LVEDD)</measure>
    <time_frame>Baseline and three months</time_frame>
    <description>The end-diastolic dimension of the left ventricle (in mm) was measured with 2D echocardiography performed by experienced technicians using Acuson Sequoia Echocardiography System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Biomarker Level BNP</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>B-type natriuretic peptide, measured pg/mL at baseline and post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-sensitivity C-reactive Protein (hsCRP) as a Cardiac Biomarker</measure>
    <time_frame>Baseline, Three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Troponin I (cTnI)</measure>
    <time_frame>Baseline, Three months</time_frame>
    <description>Participants with cTnI ≥0.04 ng/mL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Heart Failure, Congestive</condition>
  <arm_group>
    <arm_group_label>active treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>atorvastatin 10mg QD x 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matched placebo QD x 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>atorvastatin 10mg PO QD</description>
    <arm_group_label>active treatment</arm_group_label>
    <other_name>lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matched placebo Qd x 3 months</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age≥18 years old

          -  LVEF ≤ 35%, as documented by echocardiography, radionuclide ventriculography, gated
             SPECT, or contrast ventriculography within past 6 months

          -  Symptomatic HF (NYHA II-IV) or current NYHA I with history of symptomatic HF within
             the last year

          -  Stable doses of optimal HF medical therapy, unless documented contraindication.

        Exclusion Criteria:

          -  Ischemic etiology of HF, defined as the presence of at least one of the following four
             criteria; angiographic evidence of &gt; 50% lesion in 1 or more of the 3 major epicardial
             vessels; history of myocardial infarction; history of revascularization procedure;
             evidence of significant perfusion defect in the setting of ischemic symptoms.

          -  Clinical indication for statin treatment - coronary artery, cerebrovascular, or
             peripheral vascular disease

          -  Major cardiovascular event or surgical procedure within past 8 weeks

          -  LDL&lt;70 mg/dL

          -  HF secondary to congenital heart disease or uncorrected valvular disease

          -  Treatment with statin within past 2 months

          -  Pregnancy

          -  Contraindication to statin: moderate liver disease, AST/ALT &gt; 150 U/ L, known
             hypersensitivity

          -  Likely to receive heart transplant within 3 months

          -  Known peripheral or autonomic neuropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tamara B Horwich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA Division of Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ahmanson-UCLA Cardiomyopathy Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Horwich TB, Middlekauff HR. Potential autonomic nervous system effects of statins in heart failure. Heart Fail Clin. 2008 Apr;4(2):163-70. doi: 10.1016/j.hfc.2008.01.004.</citation>
    <PMID>18433696</PMID>
  </reference>
  <reference>
    <citation>Horwich TB, MacLellan WR. Atorvastatin and statins in the treatment of heart failure. Expert Opin Pharmacother. 2007 Dec;8(17):3061-8. Review.</citation>
    <PMID>18001265</PMID>
  </reference>
  <results_reference>
    <citation>PubMed ID 22041323</citation>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 4, 2005</study_first_submitted>
  <study_first_submitted_qc>October 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2005</study_first_posted>
  <results_first_submitted>April 1, 2019</results_first_submitted>
  <results_first_submitted_qc>March 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 20, 2020</results_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Tamara Horwich</investigator_full_name>
    <investigator_title>Tamara Horwich, MD, MS</investigator_title>
  </responsible_party>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Hydroxymethylglutaryl-CoA Reductase Inhibitors</keyword>
  <keyword>Sympathetic Nervous System</keyword>
  <keyword>Ventricular Remodeling</keyword>
  <keyword>Chemokines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active Treatment</title>
          <description>atorvastatin 10mg QD x 3 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>matched placebo QD x 3 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Underwent status II heart transplant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Treatment</title>
          <description>atorvastatin 10mg QD x 3 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>matched placebo QD x 3 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="14"/>
                    <measurement group_id="B2" value="49" spread="17"/>
                    <measurement group_id="B3" value="48" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>LVEF (Left Ventricular Ejection Fraction)</title>
        <description>Left ventricular ejection fraction was assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks).</description>
        <time_frame>baseline and three months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>atorvastatin 10mg QD x 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matched placebo QD x 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>LVEF (Left Ventricular Ejection Fraction)</title>
          <description>Left ventricular ejection fraction was assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks).</description>
          <units>percent ejection fraction</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline LVEF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="6"/>
                    <measurement group_id="O2" value="28" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 month LVEF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" spread="6"/>
                    <measurement group_id="O2" value="24" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>paired t test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Muscle Sympathetic Nerve Activity (by Sympathetic Microneurography)</title>
        <time_frame>Baseline and three months</time_frame>
        <population>Eighteen subjects had baseline and final sympathetic microneurographic tracings that were technically adequate for analysis. Reasons for inadequate microneurographic tracing were: 1) inability of investigators to locate sympathetic nerve on baseline or final study; or 2) inability of patient to tolerate discomfort of the procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>atorvastatin 10mg daily for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matched placebo daily for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Sympathetic Nerve Activity (by Sympathetic Microneurography)</title>
          <population>Eighteen subjects had baseline and final sympathetic microneurographic tracings that were technically adequate for analysis. Reasons for inadequate microneurographic tracing were: 1) inability of investigators to locate sympathetic nerve on baseline or final study; or 2) inability of patient to tolerate discomfort of the procedure.</population>
          <units>bursts per minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" spread="3"/>
                    <measurement group_id="O2" value="39" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Three months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" spread="5"/>
                    <measurement group_id="O2" value="38" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular End-diastolic Dimension (LVEDD)</title>
        <description>The end-diastolic dimension of the left ventricle (in mm) was measured with 2D echocardiography performed by experienced technicians using Acuson Sequoia Echocardiography System</description>
        <time_frame>Baseline and three months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>atorvastatin 10mg daily for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matched placebo daily for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End-diastolic Dimension (LVEDD)</title>
          <description>The end-diastolic dimension of the left ventricle (in mm) was measured with 2D echocardiography performed by experienced technicians using Acuson Sequoia Echocardiography System</description>
          <units>Millimeters (mm)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline LVEDD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" spread="12"/>
                    <measurement group_id="O2" value="28" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Three months LVEDD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" spread="6"/>
                    <measurement group_id="O2" value="24" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Biomarker Level BNP</title>
        <description>B-type natriuretic peptide, measured pg/mL at baseline and post-treatment</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>atorvastatin 10mg QD x 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matched placebo QD x 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Biomarker Level BNP</title>
          <description>B-type natriuretic peptide, measured pg/mL at baseline and post-treatment</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175" lower_limit="36" upper_limit="472"/>
                    <measurement group_id="O2" value="66" lower_limit="29" upper_limit="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Three Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107" lower_limit="34" upper_limit="173"/>
                    <measurement group_id="O2" value="67" lower_limit="21" upper_limit="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High-sensitivity C-reactive Protein (hsCRP) as a Cardiac Biomarker</title>
        <time_frame>Baseline, Three months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>atorvastatin 10mg daily for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matched placebo daily for three months</description>
          </group>
        </group_list>
        <measure>
          <title>High-sensitivity C-reactive Protein (hsCRP) as a Cardiac Biomarker</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.6" upper_limit="4.4"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Three months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit=".05" upper_limit="5.7"/>
                    <measurement group_id="O2" value="3.4" lower_limit="1.1" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Troponin I (cTnI)</title>
        <description>Participants with cTnI ≥0.04 ng/mL</description>
        <time_frame>Baseline, Three months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>atorvastatin 10mg daily for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matched placebo daily for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Troponin I (cTnI)</title>
          <description>Participants with cTnI ≥0.04 ng/mL</description>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Three Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active Treatment</title>
          <description>atorvastatin 10mg QD x 3 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>matched placebo QD x 3 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tamara B Horwich, MD</name_or_title>
      <organization>Ahmanson-UCLA Cardiomyopathy Center</organization>
      <phone>310-825-8676</phone>
      <email>thorwich@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

